This trial is terminated!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Atopic Dermatitis
and you are
over 18
years old
Phase
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This is a 3-part study to assess the safety, tolerability, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of MK-8226 in participants with moderate to severe atopic dermatitis. Part 1 (multiple rising dose study) objectives were to find the maximum tolerated dose (MTD) of MK-8226 and to assess safety and PK. Part 2 objectives were to determine safety, PK, and preliminary efficacy. Part 3 objectives were to further define safety and PK, and explore MK-8226 PK/PD to model the optimal dose range for future studies. The study was terminated early due to business reasons on 08 May 2014; final results from an analysis for Part 1 (efficacy, PK, safety, immunogenicity) and Part 2 (safety, immunogenicity) are summarized.

Provided treatments

  • Drug: MK-8226
  • Drug: Placebo
Tris trial is registered with FDA with number: NCT01732510. The sponsor of the trial is Merck Sharp & Dohme Corp. and it is looking for 65 volunteers for the current phase.
Official trial title:
A Phase Ib Randomized, Double-Blinded, Placebo-Controlled Multiple Rising Dose Clinical Trial to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MK-8226 in Patients With Moderate to Severe Atopic Dermatitis